Efpeglenatide Peptide: Exendin-Based GLP-1 RA and AMPLITUDE-O Evidence

Efpeglenatide is an investigational peptide drug in the glucagon-like peptide-1 receptor agonist, or GLP-1 RA, family. Unlike the human-GLP-1-based agents that dominate pharmacy shelves, efpeglenatide is built on exendin-4, the same lizard- venom-derived scaffold behind exenatide. It reached a large cardiovascular outcomes trial and produced positive results, yet it is not an approved medicine, and that gap between strong data and no approval is the most important thing to understand about it.

This guide is educational and not medical advice. Efpeglenatide is not an approved product, is not available by prescription, and any reference dose ranges below describe what researchers studied in trials. They are not recommendations and should not be read as a protocol.

For background on the broader drug class, see our overviews of GLP-1 receptor agonists, what GLP-1 is, and the GLP-1 drugs list. Because efpeglenatide's design is all about engineering a longer-acting molecule, the peptide half-life guide is useful context too.

Efpeglenatide At A Glance

How Efpeglenatide Is Built And How It Works

Efpeglenatide targets the GLP-1 receptor, the same receptor engaged by semaglutide and liraglutide (Saxenda). Activating that receptor enhances glucose-dependent insulin secretion, suppresses glucagon when glucose is elevated, slows gastric emptying, and reduces appetite through central signaling. Those overlapping actions explain why GLP-1 RAs lower blood sugar and body weight.

What makes efpeglenatide distinct is its scaffold and its engineering. Rather than mimicking human GLP-1, it is based on exendin-4, a nonhuman peptide. A single-amino-acid modification helps it resist degradation by the enzyme dipeptidyl peptidase-4 (DPP-4), which rapidly inactivates native GLP-1. The peptide is then conjugated through a flexible linker to the fragment crystallizable (Fc) region of a human immunoglobulin (IgG4). This is Hanmi's LAPSCOVERY platform.

That antibody-fragment conjugation does two practical things. It enlarges the molecule so the kidneys clear it more slowly, and it stabilizes the peptide in circulation. Pharmacokinetic work in people with type 2 diabetes reported a half-life in the range of roughly 5.6 to 7.5 days in single-ascending-dose studies, which is what supports a once-weekly injection schedule. The long-acting design is the entire point of the molecule; if you want the general principle, the half-life explainer covers why circulating duration drives dosing frequency.

The Evidence, Honestly

Efpeglenatide is unusual among investigational peptides because it accumulated genuine phase 3 outcomes data, not just surrogate-marker studies. Sanofi ran a global program of AMPLITUDE trials covering monotherapy, add-on therapy, and a dedicated cardiovascular outcomes study.

The marquee result is AMPLITUDE-O, published in the New England Journal of Medicine in 2021 (NCT03496298). It enrolled 4,076 adults with type 2 diabetes who had either established cardiovascular disease or kidney disease plus at least one additional cardiovascular risk factor. Participants were randomized to weekly subcutaneous efpeglenatide at 4 mg or 6 mg, or to placebo, on top of usual care.

The reported findings were favorable:

• The primary major adverse cardiovascular event outcome (cardiovascular death, myocardial infarction, or stroke) occurred in 7.0% of the efpeglenatide group versus 9.2% of the placebo group, a statistically significant reduction (hazard ratio 0.73; p = 0.007 for superiority, per the NEJM report).
• A composite kidney outcome (worsening kidney function or new macroalbuminuria) occurred in 13.0% with efpeglenatide versus 18.4% with placebo.
• Benefits appeared dose-related, and an exploratory analysis suggested they were broadly consistent regardless of whether patients were also taking an SGLT2 inhibitor.

Earlier program studies rounded out the picture. AMPLITUDE-M, a once-weekly monotherapy trial in treatment-naive type 2 diabetes (Diabetes Care, 2022), tested 2, 4, and 6 mg doses and reported HbA1c and body-weight reductions versus placebo. A separate phase 2 study in adults without diabetes examined body-weight effects, consistent with the appetite and weight signals seen across the GLP-1 weight-loss class.

Here are the honest limits. AMPLITUDE-O was a diabetes cardiovascular-outcomes trial, not a dedicated obesity trial, so its weight findings should not be overstated. The program was conducted by a single sponsor and then halted for business reasons (see below), so there is no head-to-head outcomes comparison against approved agents like tirzepatide or semaglutide. Most importantly, positive trial data did not translate into a licensed product, which means there is no regulator-reviewed label defining who should use it, at what dose, or with what monitoring.

Development Status: Strong Data, No Approval

This is the crux. Sanofi licensed efpeglenatide from Hanmi and ran the large phase 3 program. In 2020, as part of a strategic decision to exit diabetes and cardiovascular research, Sanofi returned the rights to Hanmi. The AMPLITUDE-O results were still presented and published in 2021, but the commercial sponsor had already stepped away.

Hanmi has since discussed repositioning the molecule, including toward obesity, but as of this writing efpeglenatide has no marketing approval from the FDA, EMA, or other major regulators for any indication. It remains investigational. That status is not a technicality. It means there is no approved prescribing information, no manufacturing-and-labeling standard you can verify, and no legitimate consumer supply chain.

Safety Signals From The Trials

Efpeglenatide's safety profile in trials mirrored the GLP-1 receptor agonist class, where gastrointestinal effects are the dominant and dose-limiting issue. Because safety was characterized only in monitored studies, the table below describes trial-context signals, not a real-world label.

For a fuller class-level discussion, see our guide to GLP-1 side effects.

How To Evaluate An Efpeglenatide Claim

Investigational peptides attract marketing language that outruns the evidence. A few questions keep claims honest.

First, is approval status stated plainly? Any source implying efpeglenatide is a purchasable, ready-to-use weight-loss peptide is misleading. It is investigational and was not brought to market.

Second, is trial data being presented as a dosing recommendation? The 4 mg and 6 mg weekly figures come from controlled trials in specific populations. They describe what was studied, not what anyone should self-administer.

Third, is the outcomes context preserved? AMPLITUDE-O studied high-risk type 2 diabetes patients for cardiovascular and renal endpoints. Borrowing its favorable numbers to sell a generic "fat-loss peptide" strips away the population and purpose that made the data meaningful.

Fourth, does the source acknowledge the discontinued program? A balanced discussion notes that a major sponsor walked away and the molecule lacks an approved label, rather than presenting only the positive headlines.

Fifth, is it conflating efpeglenatide with approved agents? It is in the same class as semaglutide and tirzepatide, but being in a class is not the same as being equivalent, approved, or available. The same caution applies to other mechanism-adjacent compounds like pramlintide and the broader peptides-for-weight-loss category.

Bottom Line

Efpeglenatide is a well-engineered, exendin-based GLP-1 receptor agonist with a genuinely strong evidence highlight: the AMPLITUDE-O trial showed reductions in major cardiovascular events and adverse kidney outcomes in high-risk type 2 diabetes. Its antibody-fragment design extends its half-life enough for once-weekly dosing, and earlier studies showed expected glucose-lowering and weight effects.

But the evidence story and the availability story diverge sharply. The original commercial sponsor returned the rights and exited the therapeutic area, and the molecule has no marketing approval for diabetes, weight loss, or anything else. There is no approved label, no defined human dosing recommendation, and no legitimate supply for personal use. Efpeglenatide is best understood as a scientifically interesting, evidence-backed but still investigational compound, not a product to source or self-administer.

References

1. Gerstein HC, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. New England Journal of Medicine, 2021.

2. ClinicalTrials.gov. Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O), NCT03496298.

3. Pratley RE, et al. Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial. Diabetes Care, 2022.

4. Del Prato S, et al. Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials. Diabetes, Obesity and Metabolism, 2023.

5. Rosenstock J, et al. Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study. Diabetes, Obesity and Metabolism, 2019.

6. Yoon KH, et al. Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020.

7. Lam CSP, et al. Efpeglenatide and Clinical Outcomes With and Without Concomitant SGLT2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation, 2022.

8. American College of Cardiology. Cardiovascular and Renal Outcomes With Efpeglenatide in Type 2 Diabetes (AMPLITUDE-O) trial summary.